Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Preliminary results from a phase Ib study.

被引：0
|
作者：
Mao, Chenyu
Qian, Jiong
Gao, Yuan
Liu, Ying
Zhang, Tao
Cui, Jiuwei
Liu, Ying
Chen, Yiwei
Zhao, Li
Xu, Nong
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[2] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[4] First Hosp Jilin Univ, Changchun, Peoples R China
[5] Innovent Biol Inc, Shanghai, Peoples R China
[6] Innovent Biol Inc, Suzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16097
引用
收藏
页码：E16097 / E16097
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study
    Mao, Chenyu
    Qian, Jiong
    Gao, Yuan
    Liu, Ying
    Zhang, Tao
    Cui, Jiuwei
    Chen, Yuling
    Chen, Haonan
    Zhao, Li
    Wang, Hongli
    Xu, Nong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study
    Liu, Ming
    Wang, Kun
    Bao, Quan
    Wang, Hongwei
    Jin, Kemin
    Liu, Wei
    Luo, Jia
    Xu, Nong
    Zhang, Tao
    Xia, Yongxiang
    Shao, Guoliang
    Liu, Baorui
    Shen, Jie
    Chen, Haonan
    Long, Sixiang
    Chen, Yuling
    Zhao, Li
    Wang, Hongli
    Xing, Baocai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in first-line advanced squamous non-small cell lung cancer (sqNSCLC): Initial results from a phase Ib study.
    Zhou, Caicun
    Xiong, Anwen
    Li, Wei
    Wang, Lei
    Wu, Fengying
    Yu, Jia
    Mao, Chenyu
    Qian, Jiong
    Zheng, Yulong
    Jiang, Haiping
    Gao, Yuan
    Xiao, Cheng
    Wang, Wenxiang
    Zhuang, Wu
    Yang, Jun
    Sun, Jiya
    Wang, Hongli
    Liu, Ying
    Xu, Nong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC).
    Xu, Nong
    Shen, Lin
    Jiang, Haiping
    Zheng, Yulong
    Qian, Jiong
    Mao, Chenyu
    Zhou, Hui
    Wang, Shuyan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or Gastroesophageal Junction Carcinoma (GC/GEJC)
    Teng, L.
    Xu, N.
    Jiang, H.
    Zheng, Y.
    Qian, J.
    Mao, C.
    Zhou, H.
    Wang, S.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1759 - 1760
  • [6] Efficacy and safety of sintilimab combined with trastuzumab and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction cancer
    Liu, Zeyu
    Liu, Aina
    Li, Ming
    Xiang, Jinyu
    Yu, Guohua
    Sun, Ping
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [7] Modified Docetaxel and Cisplatin in Combination with Capecitabine (DCX) as a First-Line Treatment in HER2-Negative Advanced Gastric Cancer
    Bilici, Ahmet
    Selcukbiricik, Fatih
    Demir, Nazan
    Ustaalioglu, Bala Basak Oven
    Dikilitas, Mustafa
    Yildiz, Ozcan
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (20) : 8661 - 8666
  • [8] Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
    Jiang, Haiping
    Zheng, Yulong
    Qian, Jiong
    Mao, Chenyu
    Xu, Xin
    Li, Ning
    Xiao, Cheng
    Wang, Huan
    Teng, Lisong
    Zhou, Hui
    Wang, Shuyan
    Zhu, Donglei
    Peng, Bo
    Shen, Lin
    Xu, Nong
    BMC CANCER, 2020, 20 (01)
  • [9] Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
    Haiping Jiang
    Yulong Zheng
    Jiong Qian
    Chenyu Mao
    Xin Xu
    Ning Li
    Cheng Xiao
    Huan Wang
    Lisong Teng
    Hui Zhou
    Shuyan Wang
    Donglei Zhu
    Bo Peng
    Lin Shen
    Nong Xu
    BMC Cancer, 20
  • [10] First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
    Hardy-Bessard, Anne-Claire
    Brocard, Fabien
    Clatot, Florian
    Lortholary, Alain
    You, Benoit
    Grenier, Julien
    Martin-Babau, Jerome
    Lucas, Brigitte
    Meunier, Jerome
    Ferrero, Jean-Marc
    Savoye, Aude-Marie
    Marti, Adina
    Despax, Raymond
    Moullet, Isabelle
    Emile, George
    BREAST, 2020, 54 : 256 - 263
12345